

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ISLAND PHARMACEUTICALS LIMITED
ABN	48 641 183 842

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Albert Hansen
Date of last notice	4 April 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Kesa Partners Inc – President and controller
Date of change	26 March 2024
No. of securities held prior to change	
Albert Hansen	400,000 unlisted options exercisable at \$0.3625 expiring 30 April 2024
Kesa Partners Inc	10,937,367 fully paid ordinary shares
Class	Ordinary shares Options exercisable at \$0.06 expiring 14 March 2025
Number acquired	166,667 ordinary shares 166,667 options exercisable at \$0.06 expiring 14 March 2025
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$10,000.02
No. of securities held after change Albert Hansen Kesa Partners Inc	400,000 unlisted options exercisable at \$0.3625 expiring 30 April 2024 11,104,034 fully paid ordinary shares 166,667 options exercisable at \$0.06 expiring 14 March 2025
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in Rights Offer

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ISLAND PHARMACEUTICALS LIMITED
ABN	48 641 183 842

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Anna Lavelle
Date of last notice	18 November 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Dr Anna Lavelle <Armytage Advisory A/C>
Date of change	26 March 2024
No. of securities held prior to change	
Anna Lavelle	400,000 unlisted options exercisable at \$0.3625 expiring 30 April 2024
Dr Anna Lavelle <Armytage Advisory A/C>	100,000 fully paid ordinary shares
Class	Ordinary shares Options exercisable at \$0.06 expiring 14 March 2025
Number acquired	40,000 ordinary shares 40,000 options exercisable at \$0.06 expiring 14 March 2025

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$2,400
No. of securities held after change Anna Lavelle Dr Anna Lavelle <Armytage Advisory A/C>	400,000 unlisted options exercisable at \$0.3625 expiring 30 April 2024 140,000 fully paid ordinary shares 40,000 listed options exercisable at \$0.06 expiring 14 March 2025
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Participation in Rights Offer

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A

+ See chapter 19 for defined terms.

Interest after change	N/A
------------------------------	-----

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ISLAND PHARMACEUTICALS LIMITED
ABN	48 641 183 842

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr David Brookes
Date of last notice	18 November 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Tarandi 1996 Pty Ltd atf Dr DL Brookes Super A/C David Lionel Brookes & Elisabeth Brookes atf Dr DL Brookes Personal Super Fund – trustee and beneficiary
Date of change	26 March 2024
No. of securities held prior to change	
David Brookes	400,000 unlisted options exercisable at \$0.3625 expiring 30 April 2024
Tarandi 1996 Pty Ltd atf Dr DL Brookes Super A/C	100,000 fully paid ordinary shares
Class	Ordinary shares Options exercisable at \$0.06 expiring 14 March 2025

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number acquired	40,000 ordinary shares 40,000 options exercisable at \$0.06 expiring 14 March 2025
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$2,400
No. of securities held after change David Brookes Tarandi 1996 Pty Ltd atf Dr DL Brookes Super A/C David Lionel Brookes & Elisabeth Brookes atf Dr DL Brookes Personal Super Fund	400,000 unlisted options exercisable at \$0.3625 expiring 30 April 2024 100,000 fully paid ordinary shares 40,000 fully paid ordinary shares 40,000 listed options exercisable at \$0.06 expiring 14 March 2025
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in Rights Offer

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ISLAND PHARMACEUTICALS LIMITED
ABN	48 641 183 842

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr David Foster
Date of last notice	4 August 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Terry Foster <Foster Living Account> - beneficiary Mr Terry Foster + Ms Vickey S Foster <Foster Living Account> - beneficiary Citicorp Nominees Pty Limited – beneficiary
Date of change	26 March 2024
No. of securities held prior to change	
David Foster	5,146,829 fully paid ordinary shares 177,778 unlisted options exercisable at \$0.3125 expiring 30 April 2024 177,778 unlisted options exercisable at \$0.3750 expiring 30 April 2024 177,778 unlisted options exercisable at \$0.4375 expiring 30 April 2024
Mr Terry Foster <Foster Living Account>	13,094 fully paid ordinary shares
Mr Terry Foster + Ms Vickey S Foster <Foster Living Account>	51,470 fully paid ordinary shares
Citicorp Nominees Pty Limited	71,303 fully paid ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Ordinary shares Options exercisable at \$0.06 expiring 14 March 2025
Number acquired David Foster Mr Terry Foster + Ms Vickey S Foster <Foster Living Account>	500,000 ordinary shares 500,000 options exercisable at \$0.06 expiring 14 March 2025 20,588 ordinary shares 20,588 options exercisable at \$0.06 expiring 14 March 2025
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation David Foster Mr Terry Foster + Ms Vickey S Foster <Foster Living Account>	\$30,000.00 \$1,235.28
No. of securities held after change David Foster Mr Terry Foster <Foster Living Account> Mr Terry Foster + Ms Vickey S Foster <Foster Living Account> Citicorp Nominees Pty Limited	5,646,829 fully paid ordinary shares 177,778 unlisted options exercisable at \$0.3125 expiring 30 April 2024 177,778 unlisted options exercisable at \$0.3750 expiring 30 April 2024 177,778 unlisted options exercisable at \$0.4375 expiring 30 April 2024 500,000 listed options exercisable at \$0.06 expiring 14 March 2025 13,094 fully paid ordinary shares 72,058 fully paid ordinary shares 20,588 options exercisable at \$0.06 expiring 14 March 2025 71,303 fully paid ordinary shares

+ See chapter 19 for defined terms.

<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	Participation in Rights Offer
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ISLAND PHARMACEUTICALS LIMITED
ABN	48 641 183 842

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Paul MacLeman
Date of last notice	12 April 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Dalroar Pty Ltd <ATF MacLeman MacLeman Investment Trust> - Director of trustee and beneficiary of trust
Date of change	26 March 2024
No. of securities held prior to change	
Paul MacLeman	1 fully paid ordinary share
Dalroar Pty Ltd < ATF MacLeman MacLeman Investment Trust >	85,053 fully paid ordinary shares 2,325,000 unlisted options exercisable at \$0.3625 expiring 30 April 2024
Class	Ordinary shares Options exercisable at \$0.06 expiring 14 March 2025
Number acquired	33,572 ordinary shares 33,572 options exercisable at \$0.06 expiring 14 March 2025

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$2,014.32
No. of securities held after change Paul MacLeman Dalroar Pty Ltd < ATF MacLeman MacLeman Investment Trust >	1 fully paid ordinary share 118,625 fully paid ordinary shares 2,325,000 unlisted options exercisable at \$0.3625 expiring 30 April 2024 33,572 options exercisable at \$0.06 expiring 14 March 2025
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Participation in Rights Offer

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.